HS-14-499 Phase III  
 
An Open -Label Multicenter Study Assessing the Long -Term Safety 
of a Once- Weekly and Once -Monthly, Long -Acting Subcutaneous 
Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients 
with Opi[INVESTIGATOR_136451] P lan (SAP) 
 
 
Sponsor  
BRAEBURN PHARMACEUTICALS [ADDRESS_154852]  
Princeton, NJ [ZIP_CODE]  
Tel: ( [PHONE_3074] 
Fax: ( [PHONE_3075] 
  
Version 1.01 
 20 April  2017 
 
 
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154853] reviewed the format and content of this prospe ctive statistical analysis plan (SAP) 
and have approved it for use to analyze the HS -14-499 data. 
  
BRAEBURN PHARMACEUTICALS  
 
 
 
Sonnie Kim, Pharm. D.   
   
 
20 Apr  2017 
     
Print Name   [CONTACT_136495], Ph.D.   
  20 Apr  2017  
     
Print Name   [CONTACT_136496]	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154854]	
  OF	
  ABBREVIATION S	
  ................................ ................................ ................................ .................... 	
  5	
  
3.0	
   INTRODUCTION 	
  ................................ ................................ ................................ ................................ ......	
  6	
  
4.0	
   STUDY	
  DESCRIPTION 	
  ................................ ................................ ................................ ............................ 	
  6	
  
4.1	
   Study	
  Objectives 	
  ................................ ................................ ................................ ...................... 	
  6	
  
4.2	
   Study	
  Treatments 	
  ................................ ................................ ................................ .................... 	
  6	
  
4.3	
   Study	
  Design 	
  ................................ ................................ ................................ .............................. 	
  6	
  
4.4	
   Randomization	
  and	
  Blinding	
   ................................ ................................ ............................... 	
  7	
  
5.0	
   ANALYSIS	
  POPULATIONS 	
  ................................ ................................ ................................ .................... 	
  7	
  
5.1	
   Overall	
  Safety	
  Population 	
  ................................ ................................ ................................ .....	
  7	
  
5.2	
   Full	
  Exposure	
   Safety	
  Population 	
  ................................ ................................ ........................ 	
  7	
  
5.3	
   Efficacy	
  Population 	
  ................................ ................................ ................................ ................. 	
  7	
  
6.0	
   GENERAL	
  CONVENTIONS 	
  ................................ ................................ ................................ ..................... 	
  7	
  
6.1	
   Definition	
  of	
  Baseline 	
  ................................ ................................ ................................ .............	
   8	
  
6.2	
   Software 	
  ................................ ................................ ................................ ................................ ......	
  8	
  
6.3	
   Changes	
  to	
  Planned	
  Analyses 	
  ................................ ................................ .............................. 	
  8	
  
7.0	
   SAMPLE	
  SIZE 	
  ................................ ................................ ................................ ................................ ............	
   8	
  
8.0	
   DESCRIPTION	
  OF	
  THE	
  S TUDY	
  POPULATIONS 	
  ................................ ................................ ..............	
   8	
  
8.1	
   Disposition 	
  ................................ ................................ ................................ ................................ .	
  8	
  
8.2	
   Demographic	
  and	
  Baseline	
  Characteristics 	
  ................................ ................................ ....	
  8	
  
8.3	
   Medical	
  History 	
  ................................ ................................ ................................ ........................ 	
  9	
  
9.0	
   PRIOR	
  AND	
   CONCOMIT ANT	
   MEDICATIONS 	
  ................................ ................................ .................. 	
  9	
  
10.0	
   EFFICACY	
  ANALYSES 	
  ................................ ................................ ................................ ............................. 	
  9	
  
10.1.1	
   Efficacy	
  Variables 	
  ................................ ................................ ................................ ....................... 	
  9	
  
10.1.2	
   Urine	
  Toxicology	
  Results 	
  for	
  Illicit	
  Opi[INVESTIGATOR_2438] 	
  ................................ ................................ .	
  10	
  
10.1.3	
   Self-­‐‑reported	
  Illicit	
  Opi[INVESTIGATOR_136452] 	
  ................................ ................................ ......................... 	
  10	
  
10.1.4	
   Retention	
  in	
  Tre atment 	
  ................................ ................................ ................................ ........	
  10	
  
10.1.5	
   Retention	
  in	
   Study	
   ................................ ................................ ................................ .................. 	
  10	
  
10.1.6	
   Measures	
  of	
  Opi[INVESTIGATOR_136453] 	
  ................................ ................................ ....................... 	
  10	
  
10.1.7	
   Measures	
  of	
  Opi[INVESTIGATOR_136454] 	
  ................................ ................................ ............................... 	
  11	
  
10.1.8	
   Urine	
  Toxicology	
  Results 	
  for	
  Other	
  Drugs	
  of	
  Abuse 	
  ................................ ................ 	
  11	
  
10.1.9	
   Work	
  Prod uctivity	
  and	
  Activity	
  Impairment	
  Questionnaire	
  General	
  Health	
  
(WPAI -­‐‑GH)	
  ................................ ................................ ................................ ................................ .	
  11	
  
10.1.10	
   EQ-­‐‑5D-­‐‑5L	
  Health	
  Questionnaire	
   ................................ ................................ ....................... 	
  11	
  
10.1.11	
   Patient	
  Satisfaction	
  Scale 	
  ................................ ................................ ................................ .....	
  11	
  
11.0	
   SUMMARIES	
  OF	
  MEASURES	
  OF	
  SAFETY	
   ................................ ................................ ........................ 	
  11	
  
11.1.1	
   Extent	
  of	
  Exposure 	
  ................................ ................................ ................................ ................. 	
  11	
  
11.1.2	
   Adverse	
  Events 	
  ................................ ................................ ................................ ........................ 	
  12	
  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   4	
  of	
  20	
   	
  11.1.3	
   Laboratory	
  Assessments 	
  ................................ ................................ ................................ .....	
  12	
  
11.1.4	
   Vital	
  Signs 	
  ................................ ................................ ................................ ................................ ...	
  13	
  
11.1.5	
   Physical	
  Exam ination 	
  ................................ ................................ ................................ ............	
   13	
  
11.1.6	
   12-­‐‑Lead	
  Electrocardiogram 	
  ................................ ................................ ............................... 	
  13	
  
11.1.7	
   Injecti on	
  Site	
  Examination	
   ................................ ................................ ................................ ..	
  13	
  
11.1.8	
   C-­‐‑SSRS	
   ................................ ................................ ................................ ................................ ..........	
   13	
  
12.0	
   IDENTIFICATION	
  AND	
  S UMMARY	
  OF	
  PROTOCOL	
  D EVIATIONS 	
  ................................ ...........	
   13	
  
13.0	
   DATA	
  QUALITY	
  ASSURAN CE	
  ................................ ................................ ................................ ............	
   14	
  
14.0	
   REFERENCES 	
  ................................ ................................ ................................ ................................ ..........	
   14	
  
15.0	
   APPENDICES 	
  ................................ ................................ ................................ ................................ ..........	
   14	
  
15.1	
   Appendix	
  A	
   -­‐‑	
  List	
  of	
  Tables,	
  Listings,	
  and	
  Figures 	
  ................................ ...................... 	
  14	
  
15.2	
   Appendix	
  B	
   -­‐‑	
  Imputation	
  Algorithm	
  for	
  Partial	
  and	
  Missing	
  Dates 	
  ...................... 	
  20	
  
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154855]	
  OF	
  ABBREVIATION S	
  
Abbreviatio n Definition  
AE Adverse Event 
BPN  Buprenorphine or Buprenorphine/Naloxone  
COWS  Clinical Opi[INVESTIGATOR_136455] (may include electronic data capture systems or paper forms)  
C-SSRS Columbia -Suicide Severity Rating Scale  
ECG  Electr ocardiogram  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligram  
PT MedDRA Preferred Term  
SAE  Serious Adverse Event 
SAP Statistical Analysis Plan 
SC Subcutaneous  
SD Standard Deviation  
SL Sublingual  
SOC  MedDRA System Organ Class  
SOWS Subjective Opi[INVESTIGATOR_136456] -Emergent Adverse Event 
VAS  Visual Analog ue Scale  
WPAI -GH Work Productivity and Activity Impairment Questionnaire General Health  
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   6	
  of	
  20	
   	
  3.0   INTRODUCTION 	
  
This statistical analysis plan (SAP) is based on Protocol HS-14-499, Version  3.0, dated 18-Nov-2016.  
The purpose of this document is to provide details on study populations and on how the variables will be 
derived, how missing data will be handled, as well as details on statistical method ologie s to be used to 
analyze the safety and efficacy data from the study.   
 
The document may evolve over time, for example, to reflect the requirements of protocol amendments  or 
regulatory requests. However, the final SAP must be finalized, approved  by [CONTACT_1034] , and placed on 
file before the database is locked and treatment codes are unblinded . Deviations from the approved plan 
will be noted in the clinical study report.  
4.0   STUDY	
   DESCRIPTION 	
  
4.1   STUDY	
  OBJECTIVES 	
  
Primary Objective:  To demonstrate the safety and tolerability of C AM2038 products in 12 -month 
(48-week) buprenorphine (BPN) treatment in adult outpatients with opi[INVESTIGATOR_2427].  
 Secondary Objectives:  To evaluate efficacy of CAM2038 through several efficacy parameters, including 
urine toxicology, signs and symptoms of withdr awal and cravings in adult outpatients with opi[INVESTIGATOR_2428].   
4.2   STUDY	
  TREATMENT S	
  	
  
Following Screening, qualified patient s will be initiated on either CAM2038 q1w or q4w, based on their 
current treatment status (qualified patient s currently on sublingual (SL) BPN or seeking BPN treatment).  
Qualified patient s will be initiated or transitioned to CAM2038 q1w or q4w as follows:  
 
•  Initiation of BPN treatment – initiate with CAM2038 q1w  
•  Currently receiving SL BPN treatments – transfer to corresponding CAM2038 q1w or q4w dose 
 
Patient s will be allowed to receive supplemental BPN during the study with booster SC injections of 
CAM2038 q1w 8 mg up to a maximum dose of 40  mg CAM2038q1w per week . For patients on 
CAM2038  q4w, a maximum of two booster doses of CAM2038 q1w 8 mg SC injection s may be given 
per week. Dose adjustments (up or down titrations) will also be allowed at scheduled visits.  
4.[ADDRESS_154856] practice for long -term 
safety studies. This one -year safety study will utilize CAM2038 q1w (once weekly) and CAM2038 q4w 
(once monthly) and will have 3 phases: Screening, Treatment, and Follow -up.   
 
Patients who are currently taking SL BPN (weekly or monthly prescription visits) or i ndividuals who are 
actively seeking BPN treatment but who have not yet begun a treatment regimen, may be el igible for the 
study.  
 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154857] been exposed to CAM2038 for 12 months (48 weeks). 
All patient s will be transitioned back to usual care and followed for an  additional 4 weeks (up t o 
Week  53).  
4.[ADDRESS_154858]- baseline efficacy 
measurements .   
6.0   GENERAL	
  CONVENTIO NS	
  
Unless otherwise stated, all analyses will be performed using SAS Version 9 and all hypothesis tests will be conducted at a two -sided significance level of 0.05.  P-values will be presented with 3 decimals and p -
values that are less than 0.001 will be pr esented as <0.001. 
 
Continuous (non-survival -related) data will be summarized using descriptive statistics: number of 
observations (n), mean, standard deviation (SD), median, minimum, and maximum. Frequencies and percentages will be used to summarize categ orical (discrete) data.  Presentations of  categorical data will 
generally suppress  percentages  for items where the  count is zero in order to draw attention to the nonzero 
counts.   In general, mean, standard deviation, median, minimum, maximum, and percenta ges will be 
presented with one decimal.  
 Unless otherwise stated, c onfidence intervals, when presented, will be constructed at the two-sided 95% 
level.  For binomial variables, the 95% confidence intervals will be constructed using the normal 
approximation  without continuity correction.  
 
Data listings will present all data collected on case report forms ( CRFs ) by [CONTACT_5349], center, and patient  
number.    
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154859] a nalyses will be conducted using SAS Versio n 9.2 or higher .   
6.3   CHANGES	
  TO	
  PLANNED	
  A NALYSES	
  
Draft versions of the SAP will be numbe red sequentially as Version 0.0 i. The final approved version will 
be numbered as Ver sion 1.00. Revisions after the “Final” version will be numbered as Version 1.0x. The 
clinical study r eport will document any changes made after the final version approved before database 
lock. 
7.[ADDRESS_154860] 48 weeks of CAM2038 exposure will be needed for the safety 
assessments. Approximately 228 patient s will be enrolled initially into this study with an estimated drop -
out rate of 50% to ensure a total of [ADDRESS_154861] 100 subjects had been exposed to CAM2038  for 12 months (48 weeks). Ho wever, a 
decision was made to allow all enrolled subjects to complete the entire treatment period and to not end the 
study after at least [ADDRESS_154862] include a population descriptor (e.g., pre-defined populations: overall 
safety population, full exposure safety population and efficacy population ) in the title . 
8.[ADDRESS_154863] of age, sex, ethnicity,  and race using 
descriptive statistics.  
 
Demographic data including age, race, ethnicity, and gender, as well as baseline clinical characteristics 
will be summarized. Age will  be calculated based on the following conditional algorithm:  
 
•  Has the patient had his/her  birthday this year?  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   9	
  of	
  20	
   	
  o  Yes, then AGE = (year of informed consent) – (year of birth).  
o  No, then AGE = (year of informed consent) – (year of birth) – 1. 
 
Clinical baseline  characteristics summarized will include , if available,  weight, body mass index , region 
(Europe, the US and Australia) , type of primary opi[INVESTIGATOR_2441], years of drug use, when first diagnosed with 
opi[INVESTIGATOR_2561] , proportion of patients previously treated fo r opi[INVESTIGATOR_136457] .  
8.3   MEDICAL	
  HISTORY 	
  
Medical history will be coded using  the Medical Dictionary for Regulatory Activities (MedDRA ). 
Medical history  will be summarized and listing s will be present ed.   
9.0   PRIOR 	
  AND	
   CONC OMITANT 	
  MEDICATIONS 	
  
All medications recorded on the CRFs will be coded using the WHO DRUG Dictionary . Prior and 
concomitant medications will be summarized by [CONTACT_2220]  (ATC) Class Level [ADDRESS_154864] administration of any study treatment component will be included in the concomitant medications 
table. All other medications will be included in both the prior and concomitant medications tables.  
 Prior and Concomitant medication will be summarized for the safety population s. 
10.0   EFFICACY	
  ANALYSES 	
  
10.1.1   EFFICACY	
  VARIABLES 	
  
This is a long -term safety study  and e fficacy evaluation is not the primary objective of the study . All 
efficacy variables will be summarized  using the efficacy population . The efficacy variables will include 
the following:  
•  Urine toxicology results for illicit opi[INVESTIGATOR_2438]  
•  Self-reported illicit opi[INVESTIGATOR_2441]  
•  Retention (%) in treatment  (identical to exposure) 
•  Retention (%) in study  
•  Measures of opi[INVESTIGATOR_43351]:  
o  Clinic al Opi[INVESTIGATOR_2433] (COWS)  
o  Subjective Opi[INVESTIGATOR_2433] (SOWS)  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   10	
  of	
  20	
   	
  •  Measures of opi[INVESTIGATOR_2506]:  
o  Desire to Use Visual Analogue S cale (VAS)  
o  Need to Use VAS  
•  Urine toxicology results for other drugs of abuse  
•  Work Productivity and Activity Impairment Q uestionnaire General Health (WPAI -GH) 
•  EQ-5D-5L Health Questionnaire  
•  Patient Satisfaction Scale  
10.1.2   URINE	
  TOXICOLOGY	
  RES ULTS	
   FOR	
  ILLICIT	
  OPI[INVESTIGATOR_136458] (with and without self-reports of 
illicit opi [INVESTIGATOR_2441]) will be presented by [CONTACT_136476] . Mean percentage of urine samples negative for 
illicit opi[INVESTIGATOR_2438] (with and without self -reports of illicit opi[INVESTIGATOR_2441]) will also be presented. Additionally, 
mean urine samples negative for illicit opi[INVESTIGATOR_2438] (with an d without self -reports) will be presented by [CONTACT_136477].  Due to the 
flexible visit schedule, no imputation of missing data will be applied.  
10.1.3   SELF-­‐‑ REPORTED	
  ILLICIT	
  OPI [INVESTIGATOR_136459] . Mean 
percentage of reports of no illicit opi[INVESTIGATOR_136460]. Due to the flexible visit schedule, no 
imputation of missing data will be applied.  
10.1.[ADDRESS_154865] dose of CAM2038 to the date of study discontinuation.  
 
Durat ion in study will be summarized by [CONTACT_136478] . Data 
will also be presented using Kaplan -Meier plots.  
10.1.6   MEASURES	
  OF	
  OPI[INVESTIGATOR_136461]	
  W ITHDRAWAL	
  
Measures  of withdrawal  include  COWS  and SOWS.  The COWS  is comprised  of 11 items, each with a 
score of 0 through  4 or 5.  Higher  scores  are associated  with greater  withdrawal  symptoms.  The items  are 
meant  to be objective  measures  of a patient’s  withdrawal  symptoms  (e.g.,  resting  pulse  rate). The SOWS 
is comprised  of 16 items  each with a score of 0 through  4. Higher  scores  are associated  with greater  
withdrawal  symptoms.  The items  are statements  that are evaluated  by [CONTACT_136479] e 
subjective  (e.g.,  I feel anxious,  0 = not at all, 1 = a little, 2 = moderately,  3 = quite  a bit, 4 = extremely).   
 If there  are >=3 (i.e., >=20%)  missing  items  in the COWS  scale  at a given  visit or >=4 (i.e., >20%)  
missing  items  in the SOWS scale at a given  visit,  the COWS/SOWS  score for that visit will be missing.  If 
there  are [ADDRESS_154866]  of the calculated  total and 11/(11 - # missing)  will be used for the COWS  score 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154867]  of the calculated  total and 16/(16  - # missing)  will be used for the 
SOWS score.  
 
COWS and SOWS data will be presented by [CONTACT_765]. Data will also be presented  as change from baseline by 
[CONTACT_136480] -baseline values. Negative changes are thus indicative of 
improvement.  
10.1.7   MEASURES	
  OF	
  OPI[INVESTIGATOR_136462]  100 mm VAS ; “Since your last scheduled assessment visit, indicate your worst or strongest 
desire/need to use opi[INVESTIGATOR_136463] 0 = No desire /need  to use and 100 = Maximum  desire /need to use on 
this scale” .  
 
VAS data for Desire to Use and Need to Use will be presented  by [CONTACT_765].  Data will also be presented as 
change from baseline by [CONTACT_136480] -baseline values. Negative changes 
are thus indicative of improvement. 
10.1.8   URINE	
  TOXICOLOGY	
  RES ULTS	
   FOR	
  OTHER	
  DRUGS	
  OF	
  A BUSE 	
  
Percentage of patients with  urine samples positive for other drugs of abuse will be presented by [CONTACT_136481]. Mean percentage of urine samples positive for other drugs of abuse will also be presented. Due to 
the flexible visit schedule, no imputation of missing data will be appli ed.  
10.1.9   WORK	
  P RODUCTIVITY	
  AND	
  ACTI VITY	
  IMPAIRMENT	
  QUES TIONNAIRE	
  
GENERAL	
  HEALTH	
  (WPAI -­‐‑GH)	
  
Data	
  for	
  WPAI -­‐‑GH	
  will	
  be	
  presented	
  by	
  [CONTACT_136482].	
   	
  
10.1.10    EQ-­‐‑5D-­‐‑5L	
  HEALTH	
  QUESTIONNA IRE	
  
Data for EQ -5D-5L will be presented over time.  
10.1.11    PATIENT	
  SATISFACTION 	
  SCALE 	
  
Patient sa tisfaction scale scores will be presented by [CONTACT_136483].  
11.0   SUMMARIES 	
  OF	
  MEASURES	
  OF	
  SAFET Y	
  
Safety analyses will be performed for the overall safety population  and full exposure safety population .   
 
Safety evaluations will be based on the incidence, int ensity and type of adverse events  (AEs), as well as 
on clinically significant changes in the patient ’s vital signs, electrocardiogram ( ECG ), clinical laboratory 
results  and injection  site examination s. 
11.1.1   EXTENT	
  OF	
  EXPOSURE	
  
Summary statistics (number and perc entage) of weeks of exposure to study drug (i.e. from the date of  the 
first injection  to the date of the last injection  plus [ADDRESS_154868] treatment was CAM2038 q1w) will be presented . Number of pa tients, number of 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   12	
  of	
  20	
   	
  injections and exposure years will be presented by [CONTACT_2715], treatment (CAM2038 q1w and CAM2038 q4w)  
and in total .  
11.1.2   ADVERSE	
  EVENTS 	
  
Each AE and serious adverse event ( SAE ) term recorded on the CRFs by [CONTACT_92869] 
(SOC) and will be mapped to a preferred term (PT) using the MedDRA dictionary. T he Investigator will 
assess AE  severity and relationship to the study treatment.  
 
A treatment -emergent adverse event (TEAE) is defined as any AE with an onset date on or after the date 
of the first study treatment , or any ongoing event started on the date of the first dose that worsens in 
severity. Only AEs with an onset date prior to the date of the last dose + [ADDRESS_154869] related event. In addition, SAE s by [CONTACT_136484]. Deaths and 
SAEs will be summarized similarly to AEs. All AE tables will also include the total number of events, 
counting multiple events per patient.  
Injection -related AEs, other (non -injection  related) AEs as well as all AEs will be presented. Summaries 
of these AE subsets will be presented for the following categories:  
•  Study drug -related  
•  Intensity  
•  Serious  
•  AEs which led to treatment /study  discon tinuation  
•  SAEs which led to treatment /study  discontinuation  
•  AEs occurring in 5% or greater of patients (by [CONTACT_11702]) 
 
In the AE summary, the SOCs and the PTs within each SOC will appear in descending order of 
frequency .   
 Frequencies of deaths and hospi[INVESTIGATOR_136464].  
Other safety analyses will be performed as appropriate  
11.1.[ADDRESS_154870] in each laboratory category ( hematology, chemistry, urinalysis, and coagulation 
profile). Shift tables will be presented for shifts from baseline lab  categories  to end of study laboratory 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   13	
  of	
  20	
   	
  category.  The three laboratory categories will be:  L ( below lower bound of normal range ), N (within 
normal range) , and H (above high er bound of normal range) .    
If a lab value is reported using a non -numeric qualifier (e.g., les s than (<) a certain value, or greater than 
(>) a certain value), the given numeric value will be used in the summary statistics, ignoring the non -
numeric qualifier.  
If a patient has repeated laboratory values for a given time point, the value from the fir st evaluation at that 
time point will be used for summarization purposes. For the purpose of determining baseline, the last non -
missing observation on or prior to  first dose of CAM2038 .   
11.1.4   VITAL	
  SIGNS	
  
Vital signs will be assessed over time . Vital sign  value s and change from baseline in the vital signs will 
be summarized.  
11.1.5   PHYSICAL	
  EXAM INATION 	
  
Physical examination  data at Screening will be summarized . 
11.1.6   12-­‐‑LEAD	
  ELECTROCARDIOGR AM	
  
12-Lead ECGs will be assessed over time . The ECG variables will include ventricular heart rate and the 
PR, QRS, QT, QTcB and QTcF intervals. The ECGs will be signed and dated by a medically -qualified 
individual to confirm review of the ECG and verify whether any abnormalities are clinically significant.  
 
Number and percent of patients in  each ECG finding category (normal, abnormal not clinically 
significant, and abnormal and clinically significant), wi ll be summarized for each visit . Summary 
statistics will be presented for the actual value and change for each ECG parameter.  
 
The number a nd percent of patient s with QT, QTcB and QTcF intervals < 450 msec, 450 to <480, 480 to 
<500 and greater than/equal to 500 msec at each visit and overall (at any visit) will be summarized. Additionally, the number and percentage of patient s with increases  in these parameters of <30 msec, 30 to 
<60 msec and greater than/equal to 60 msec will be summarized at each visit.  
11.1.7   INJECTION 	
  SITE	
  EXAMINATION	
  
The injection  site will be visually inspected for evidence of erythema, edema, itching, pain, infection, 
bleedin g, abnormal healing and any other abnormalities .   
 
AEs that are believed to be associated with injection  procedures will be summarized similarly to the 
summaries for other AEs (not associated with injection  procedures).  
11.1.8   C-­‐‑SSRS	
  
Data on Columbia -Suicide Sev erity Rating Scale (C -SSRS)  will be summarized over time.  
12.0   IDENTIFICATION	
  AND	
  SUMMARY	
  OF	
  PROTOCOL	
  D EVIATIONS 	
  
Major protocol deviations from entry criteria and treatment compliance will be summarized as far as they 
can be extracted from numeric or coded stu dy data.  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑[ADDRESS_154871] 
the investigator’s records by [CONTACT_11200] (source document verification) and by [CONTACT_136485] 
a drug –dispen sing log by [CONTACT_093].  Collected data will be entered into a computer database and 
subject  to electronic and manual quality assurance procedures.  
14.0   REFERENCES 	
  
Not	
  applicable. 	
  
15.0   APPENDICES	
  
15.1   APPENDIX	
  A	
  -­‐‑ 	
  LIST	
  OF	
  TABLES,	
  LIST INGS,	
  AND	
  FIGURES	
  	
  
List of Tabl es 
Number  Title  
TABLE [IP_ADDRESS] Disposition of Enroll ed Patients (Overall Safety Population)  
TABLE [IP_ADDRESS] Disposition of Enroll ed Patients (Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Disposition of Enroll ed Patients ( Efficacy  Population)  
TABLE 14 .1.2.1 Demographics ( Overall Safety Population)  
TABLE [IP_ADDRESS]  Demographics ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS]  Demographics ( Efficacy  Population)  
TABLE [IP_ADDRESS]  Baseline Clinical Characteristics ( Overall Safety Population)  
TABLE [IP_ADDRESS]  Baseline Clinical Characteristics ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS]  Baseline Clinical Characteristics ( Efficacy  Population)  
TABLE [IP_ADDRESS]  Summary of Psychiatric History ( Overall Safety Population)  
TABLE [IP_ADDRESS]  Summary of Psychiatric Hi story ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS]  Summary of Psychiatric History ( Efficacy  Population)  
TABLE [IP_ADDRESS].1  Prior Medications ( Overall Safety Population)  
TABLE [IP_ADDRESS].2  Prior Medications ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS] .3 Prior Medications ( Efficacy  Population)  
TABLE [IP_ADDRESS].1  Concomitant Medications ( Overall Safety Population)  
TABLE [IP_ADDRESS].2  Concomitant Medications ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS].3  Concomitant Medications ( Efficacy  Population)  
TABLE [IP_ADDRESS]  Substance Abuse Treatment History ( Overall Safety Population)  
TABLE [IP_ADDRESS]  Substance Abuse Treatment History ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS]  Substance  Abuse Treatment History ( Efficacy  Population)  
TABLE [IP_ADDRESS]  Summary  of Urine Toxicology Results for Illicit O pi[INVESTIGATOR_136465] -
Reported Illicit Opi[INVESTIGATOR_2480] U se over Time (Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Urine Toxicology Results for Illicit Opi[INVESTIGATOR_136466] -
Reported Illicit Opi[INVESTIGATOR_2480] U se over Time (Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Mean Percentage of Urine Toxicology Results for Illicit O pi[INVESTIGATOR_136467] -Reported Illicit Opi[INVESTIGATOR_2480] U se (Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Mean Percentage of Urine Toxicology Results f or Illicit O pi[INVESTIGATOR_136468]	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   15	
  of	
  20	
   	
  Without Self -Reported Illicit Opi[INVESTIGATOR_2480] U se (Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Mean Percentage of Urine Toxicology Results for Illicit Opi[INVESTIGATOR_136469] -Reported Illicit Opi[INVESTIGATOR_136470] (New to Treatment [Yes/No])  
TABLE [IP_ADDRESS] Summary of Mean Percentage of Urine Toxicology Results for Illicit O pi[INVESTIGATOR_136471] -Reported Illicit Opi[INVESTIGATOR_2480] U se by [CONTACT_136486] (New 
to Treatment [Yes/No]) ( Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Self -Reported Illicit Opi[INVESTIGATOR_2480] U se over Time  (Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Mean Percentage of Self-Reported Illicit Opi[INVESTIGATOR_2480] U se (Efficacy  
Population)  
TABLE [IP_ADDRESS] Summary of Retention (%) in T reatment  over Time ( Efficacy  Population)  
TABLE [IP_ADDRESS] Time to End of Retention in T reatment  (Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Retention (%) in Study over Time ( Efficacy  Population)  
TABLE [IP_ADDRESS] Time to End of Retention in Study ( Efficacy  Population)  
TABLE 1 [IP_ADDRESS]  Summary of Retention (%) in T reatment  over Time by [CONTACT_136487] (New to Treatment [Yes/No]) ( Efficacy  Population)  
TABLE [IP_ADDRESS] Time to End of Retention in T reatment  by [CONTACT_136486] (New to 
Treatment [Yes/No]) ( Efficacy  Population)  
TABLE 14.2.6 Summary of Clinical Opi[INVESTIGATOR_2433] (COWS) over Time ( Efficacy  
Population)  
TABLE 14.2.7 Summary of Subjective Opi[INVESTIGATOR_136472]  (SOWS) over Time ( Efficacy  
Population)  
TABLE 14.2.8 Summary of Desire to Use VAS  over Time ( Efficacy  Population)  
TABLE 14.2.9 Summary of Need to Use VAS  over Time ( Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Urine Toxicology Results for Other Drugs of Abuse over Time 
(Efficacy  Population)  
TABLE [IP_ADDRESS] Summary of Mean Percent age of Urine Toxicology Results for Other Drugs of 
Abuse (Efficacy  Population)  
TABLE 14.2.11 Summary of Work Productivity and Activity Impairment Questionnaire General 
Health (WPAI -GH) by [CONTACT_136488] (Efficacy Population)  
TABLE 14.2.12 Summary of EQ -5D-5L Health Questionnaire Data over Time (Efficacy 
Population)  
TABLE 14.2.13 Summary of Patient Satisfaction Scale Scores by [CONTACT_136488] (Efficacy 
Population)  
TABLE 14.3 .1.1 Summary of CAM2038 Exposure  over Time  (Overall Safety Population) 
TABLE 14.3 .1.2 Summary of CAM2038 Exposure  over Time  (Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of CAM2038 Exposure by [CONTACT_136489] (Overall 
Safety Population)  
TABLE [IP_ADDRESS] Summary of CAM2038 Exposure by [CONTACT_136490] (Full 
Exposure Safety Population)  
TABLE 14.3 .2.1 Summary of All Adverse Events by [CONTACT_1196], Preferred Term, and 
Relationship ( Overall Safety Population)  
TABLE 14.3 .2.2 Summary of All Adverse Events by [CONTACT_1196], Preferred Term, and 
Relationship ( Full Exposure Safety Population)  
TABLE 14.3 .2.3 Summary of All Injection -Related Adverse Events by [CONTACT_1196], 
Preferred Term, and Relationship ( Overall Safety Population)  
TABLE 14.3 .2.4 Summary of All Injection -Related Adverse Even ts by [CONTACT_1196], 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   16	
  of	
  20	
   	
  Preferred Term, and Relationship ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of All Injection -Related Adverse Events by [CONTACT_9560], Time to 
Onset and Duration (Overall Safety Population)  
TABLE [IP_ADDRESS] Summary o f All Injection -Related Adverse Events by [CONTACT_9560], Time to 
Onset and Duration (Full Exposure Safety Population)  
TABLE 14.3 .2.7 Summary of All Non-Injection Related Adverse Events by [CONTACT_1196], 
Preferred Term, and Relationship ( Overall Safety Population)  
TABLE 14.3 .2.8 Summary of All Non-Injection Related Adverse Events by [CONTACT_1196], 
Preferred Term, and Relationship ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of All Suspected to Be Drug -Related Adverse Events by [CONTACT_11875] m Organ 
Class and Preferred Term ( Overall Safety Population)  
TABLE [IP_ADDRESS] Summary of All Suspected to Be Drug -Related Adverse Events by [CONTACT_52140] ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of All Injection Rela ted Suspected to Be Drug -Related Adverse Events 
by [CONTACT_39960] ( Overall Safety Population)  
TABLE [IP_ADDRESS] Summary of All Injection Suspected to Be Drug -Related Adverse Events by 
[CONTACT_39960] ( Full Exposur e Safety Population)  
TABLE [IP_ADDRESS] Summary of All Non-Injection Related Suspected to Be Drug -Related Adverse 
Events by [CONTACT_39960] ( Overall Safety Population)  
TABLE [IP_ADDRESS] Summary of All Non-Injection Suspected to Be Drug -Related Adverse Events by 
[CONTACT_39960] ( Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of All Adverse Events by [CONTACT_1196] , Preferred Term,  and 
Severity (Overall Safety Population)  
TABLE [IP_ADDRESS] Summary of All Adve rse Events by [CONTACT_1196] , Preferred Term,  and 
Severity (Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of All Injection -Related Adverse Events by [CONTACT_1196] , 
Preferred Term,  and Severity  (Overall Safety Population)  
TABLE [IP_ADDRESS] Summary of All Injection -Related Adverse Events by [CONTACT_1196] , 
Preferred Term,  and Severity  (Full Exposure Safety Population)  
TABLE [IP_ADDRESS] Summary of All Non-Injection Related Adverse Events by [CONTACT_1196] , 
Preferred Term,  and Severity  (Overall Safety Population)   
TABLE [IP_ADDRESS] Summary of All Non-Injection Related Adverse Events by [CONTACT_1196] , 
Preferred Term,  and Severity  (Full Exposure Safety Population)  
TABLE 14.3. 5.1.[ADDRESS_154872] Common (at least 5%) Adverse Events by S ystem Organ 
Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 5.1.2  Summary (number of patient s and number of events) of Most Common (at least 
5%) Non-Serious Adverse Events by [CONTACT_39960] 
(Overall Safety Population ) 
TABLE 14.3. 5.1.3  Summary (number of patient s and number of events) of Serious Adverse Events 
by [CONTACT_39960] ( Overall Safety Population)  
TABLE 14.3. 5.[ADDRESS_154873] Common (at least 5%) Adverse Events by [CONTACT_12360] a nd Preferred Term ( Full Exposure Safety Population)  
TABLE 14.3. 5.[ADDRESS_154874] Common (at least 5%) Injection -Related Adverse Events by 
[CONTACT_39960] ( Overall Safety Population)  
TABLE 14.3. 5.[ADDRESS_154875] Common Injection -Related (at least 5%) Adverse Events by 
[CONTACT_39960] ( Full Exposure Safety Population)  
TABLE 14.3. 5.[ADDRESS_154876] Common (at least 5%) Non-Injection Related Adverse Events 
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   17	
  of	
  20	
   	
  by [CONTACT_39960] ( Overall Safety Population)  
TABLE 14.3. 5.[ADDRESS_154877] Common Non-Injection Related (at least 5%) Adverse Events 
by [CONTACT_39960] ( Full Exposure Safety Population)  
TABLE 14.3. 6.1 Summary of All Serious Adverse Events by [CONTACT_136491] ( Overall Safety Population)  
TABLE 14.3. 6.2 Summary of All Serious Adverse Events by [CONTACT_136491] ( Full Exposure Safety Population)  
TABLE 14.3. 6.3 Summary of All Injection -Related Serious Adverse Events by [CONTACT_11875] m Organ 
Class and Preferred Term ( Overall Safety Population)  
TABLE 14.3. 6.4 Summary of All Injection -Related Serious Adverse Events by [CONTACT_52140] ( Full Exposure Safety Population)  
TABLE 14.3. 6.5 Summary of All Non-Injection Rel ated Serious Adverse Events by [CONTACT_136492] ( Overall Safety Population)  
TABLE 14.3. 6.6 Summary of All Non-Injection Related Serious Adverse Events by [CONTACT_136492] ( Full Exposure Safety Population)  
TABLE 1 [IP_ADDRESS] Summary of All Adverse Events That Lead to Treatment/ Study Discontinuation 
by [CONTACT_39960] ( Overall Safety Population)  
TABLE 14.3. 7.2 Summary of All Adverse Events That Lead to Treatment/ Study Discontinuation 
by [CONTACT_39960] ( Full Exposure Safety Population)  
TABLE 14.3. 7.3 Summary of All Injection Related Adverse Events That Lead to Treatment/ Study 
Discontinuation by [CONTACT_39960] ( Overall Safety 
Population)  
TABLE 14.3. 7.4 Summary of All Injection -Related Adverse Events That Lead to Treatment/ Study 
Discontinuation by [CONTACT_39960] ( Full Exposure 
Safety Population)  
TABLE 14.3. 7.5 Summary of All Non-Injection Related Adverse Events That Lead to 
Treatme nt/Study Discontinuation by [CONTACT_39960] 
(Overall Safety Population)  
TABLE 14.3. 7.6 Summary of All Non-Injection Related Adverse Events That Lead to 
Treatment/ Study Discontinuation by [CONTACT_39960] 
(Full Ex posure Safety Population)  
TABLE 14.3. 8.1 Summary of All Serious Adverse Events That Lead to Treatment/ Study 
Discontinuation by [CONTACT_39960] ( Overall Safety 
Population)  
TABLE 14.3. 8.2 Summary of All Serious Adverse Events That Lea d to Treatment/ Study 
Discontinuation by [CONTACT_39960] ( Full Exposure 
Safety Population)  
TABLE 14.3. 8.3 Summary of All Injection Related Serious Adverse Events That Lead to 
Treatment/ Study Discontinuation by [CONTACT_136493] P referred Term 
(Overall Safety Population)  
TABLE 14.3. 8.4 Summary of All Injection Related Serious Adverse Events That Lead to 
Treatment/ Study Discontinuation by [CONTACT_39960] 
(Full Exposure Safety Population)  
TABLE 14.3. 8.5 Summar y of All Non-Injection Related Serious Adverse Events That Lead to 
Treatment/ Study Discontinuation by [CONTACT_39960] 
(Overall Safety Population)  
TABLE 14.3. 8.6 Summary of All Non-Injection Related Serious Adverse Events That Lead to  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   18	
  of	
  20	
   	
  Treatment/ Study Discontinuation by [CONTACT_39960] 
(Full Exposure Safety Population)  
TABLE 14.3. 9.1 Summary of All Deaths and Hospi[INVESTIGATOR_602] ( Overall Safety Population)  
TABLE 14.3. 9.2 Summary of All Deaths and Hospi[INVESTIGATOR_602] ( Full Exposure Safety Population)  
TABLE 14.3. 9.3 Summary of All Injection -Related Deaths and Hospi[INVESTIGATOR_602] ( Overall Safety 
Population)  
TABLE 14.3. 9.4 Summary of All Injection -Related Deaths and Hospi[INVESTIGATOR_602] ( Full Exposure 
Safety Population)  
TABLE 1 [IP_ADDRESS] Summary of All Non-Injection Related Deaths and Hospi[INVESTIGATOR_602] ( Overall 
Safety Population)  
TABLE 14.3. 9.6 Summary of All Non-Injection Related Deaths and Hospi[INVESTIGATOR_602] ( Full 
Exposure Safety Population)  
TABLE 14. 3.10.1 Summary of Columbia -Suicide Severity Ratings  over Time  (Overall Safety 
Population)  
TABLE 14. 3.10.2 Summary of Columbia -Suicide Severity Ratings  over Time  (Full Exposure 
Safety Population)  
TABLE 14. 3.11.1 Summary of Clinical Hematology Data over Time  (Overall Safety Population)  
TABLE 14. 3.11.2 Summary of Clinical Hematology Data over Time  (Full Exposure Safety 
Population)  
TABLE 14. 3.12.1 Shift from Baseline in Laboratory Tests: Hematology ( Overall Safety 
Population)  
TABLE 14. 3.12.2 Shift from Baseline in Laboratory Tests: Hematology ( Full Exposure Safety 
Population)  
TABLE 14. 3.13.1 Summary of Clinical Chemistry Data ( Overall Safety Population)  
TABLE 14. 3.13.2 Summary of Clinical Chemistry Data ( Full Exposure Safety Population)  
TABLE 14. 3.14.1 Shift from Baseline in Laborato ry Tests: Chemistry  (Overall Safety Population)  
TABLE 14. 3.14.2 Shift from Baseline in Laboratory Tests: Chemistry (Full Exposure Safety 
Population)  
TABLE 14. 3.15.1  Summary of Clinical Coagulation Profile Data ( Overall Safety Population)  
TABLE 14. 3.15.2 Summary of Clinical Coagulation Profile Data ( Full Exposure Safety Population)  
TABLE 14. 3.16.1 Shift from Baseline in Laboratory  Tests: Coagulation Profile  (Overall Safety 
Population)  
TABLE 14. 3.16.2 Shift from Baseline in Laboratory Tests: Coagulation Profile  (Full Exposure 
Safety Population)  
TABLE 14. 3.17.1 Summary of Vital Signs over Time  (Overall Safety Population)  
TABLE 14. 3.17.2 Summary of Vital Signs over Time  (Full Exposure Safety Population)  
TABLE 14. 3.18.1 Summary of 12 -Lead ECG Results  (Overall Safety Population)  
TABLE 14. 3.18.2 Summary of 12 -Lead ECG Results  (Full Exposure Safety Population)  
TABLE 14. 3.19.1	
   Summary of 12 -Lead ECG Individual Parameters ( Overall Safety Population)  
TABLE 14. 3.19.2	
   Summary of 12 -Lead ECG Individual Parameter s (Full Exposure Safety 
Population)  
 
List of Listings  
Number  Title  
LISTING [IP_ADDRESS]  Patient Meeting  Inclusion Criteria  
LISTING [IP_ADDRESS]  Patients Meeting Exclusion Criteria  
LISTING 16.2.2	
   Protocol Deviations  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   19	
  of	
  20	
   	
  LISTING 16.2.3	
   Patient Disposition 
LISTING [IP_ADDRESS] 	
   Demographics  
LISTING [IP_ADDRESS] 	
   Psychosocial History  
LISTING [IP_ADDRESS] 	
   Medical History  
LISTING [IP_ADDRESS]  Substance Abuse History and Treatment  
LISTING [IP_ADDRESS] 	
   CAM2038  Injection  
LISTING [IP_ADDRESS] 	
   Injection  Site Examination/ Treatment Compliance  
LISTING [IP_ADDRESS]  COWS, SOWS 
LISTING [IP_ADDRESS]  Need to Use and Desire to Use VAS  
LISTING [IP_ADDRESS]  Urine Toxicology Results for Illicit Opi[INVESTIGATOR_136473] [IP_ADDRESS]  Self-Reported Illicit Opi[INVESTIGATOR_2480] U se 
LISTING [IP_ADDRESS]  Urine Toxicology Results for Other Drugs of  Abuse  
LISTING [IP_ADDRESS]  Work Productivity and Activity Impairment Questionnaire General Health 
(WPAI -GH) 
LISTING [IP_ADDRESS]  EQ-5D-5L Health Questionnaire  
LISTING [IP_ADDRESS]  Patient Satisfaction Scale  
LISTING [IP_ADDRESS]  Psychosocial Counseling  
LISTING  [IP_ADDRESS]  Adverse Events  
LISTING [IP_ADDRESS]  Serious Adverse Events  
LISTING [IP_ADDRESS]  Adverse Events That Lead to Discontinuation from Treatm ent/Study  
LISTING [IP_ADDRESS]  Adverse Events That Have Death as the Outcome  
LISTING [IP_ADDRESS]  Death Report s 
LISTING [IP_ADDRESS]  Prior and Concomitant Medications/Procedures  
LISTING [IP_ADDRESS]  Lab Test Samples  
LISTING [IP_ADDRESS]  Clinical Hematology  
LISTING [IP_ADDRESS]  Clinical Chemistry  
LISTING [IP_ADDRESS]  Clinical Coagulation Profile  
LISTING [IP_ADDRESS]  Urinalysis  
LISTING [IP_ADDRESS]  Serolo gy 
LISTING [IP_ADDRESS]  Pregnancy Test   
LISTING [IP_ADDRESS]  Pregnancies  
LISTING 16.2.[ADDRESS_154878] of Figures  
FIGURE 14.2.1  Kaplan -Meier Plot of T ime to T reatment Discontinuation (retention in treatment)  
(Efficacy  Population)  
FIGURE 14.2.2  Kaplan -Meier Plot of T ime to S tudy D iscontinuation (retention in study)  
(Efficacy  Population)  
FIGURE 14.2.3  Urine Toxicology Results for Illicit  Opi[INVESTIGATOR_5536] S upported by [CONTACT_136494]-Report ed 
Illicit Opi[INVESTIGATOR_136474] T ime (Efficacy  Population)  
FIGURE 14.2.4  Urine Toxicology Results for Illicit Opi[INVESTIGATOR_136475]-Reported Illicit 
Opi[INVESTIGATOR_136474] T ime (Efficacy  Population)  
BRAEBURN	
  PHARMACEUTICALS	
   CONFIDENTIAL 	
   Version	
   1.01—20	
  April 	
  2017 	
  
HS-­‐‑14-­‐‑499	
  SAP 	
   Page	
   20	
  of	
  20	
   	
  15.2   APPENDIX	
  B 	
  -­‐‑	
  IMPUTATION	
  ALGORITH M	
  FOR	
  PARTIAL	
  AND	
  MI SSING	
  
DATES	
  	
  
This section describes missing date imputation methods.  
 
For Adverse Events  
 
If onset date is completely missing, onset date is set to the date of first study dose date . 
If (year is present and month and day are missing) or  (year and day are present and month is missing):  
•  If year = year of first dosing , then set month and day to month and day of first dosing  
•  If year < year of first dosing , then set month and day to December 31.  
•  If year > year of first dosing , then set month and day to January 1. 
If month and year are present and day is missing:  
•  If year=year of first dosing  and   
•  If month = month of first dosing  then set day to day of first dose  
•  If month < month of first dose then set day to last day of month  
•  If month > month of first dose then set day to first day of month  
•  If year < year of first dosing  then set day to last day of month  
•  If year > year of dosing then set day to first day of month  
 
For all other cases, set onset date to date of first dosing . 
 
For Concomitant Med ications  
 Start Date:   If start date is completely missing and end date is not prior to first dosing , then the medication 
will be classified as concomitant. If start date is completely missing and end date is prior to first dosing , 
then the medication will be classified as prior.  
 
If (year is present and month and day are missing) or (year and day are present and month is missing) then 
set month and day to January 1.   If year and month are present and day is missing then set day to first day 
of month.  
 
End Date:   If end date is completely missing then the medication will be classified as concomitant. 
If (year is present and month and day are missing) or (year and day are present and month is missing) then  
set month and day to December 31.   If year and month are present and day is missing then set day to last 
day of the month.  
 Note : that if both start and end dates are missing then the medication will be classified as concomitant.  